CMTM6, positioned on the cell surface, can reduce the ubiquitination of the PD-L1 protein, thereby extend the half-life of PD-L1 in vivo, and further weakens the tumor-killing ability of T cells. This evidence concerns the gene CD274 and neoplasm.